NetTargets Inc.
01 May 2025
NetTargets is selected for the 초격차 스타트업 1000+ program to commercialize core technologies through the Micro-DIPS initiative. Leveraging our proprietary drug design platform and disease modeling AI, we are actively designing a new modality therapeutic in collaboration with partners.
Korea Institute of Startup & Entrepreneurship Development (KISED)
NetTargets will contribute its proprietary AI-based systems biology modeling technology to WOOJUNGBIO’s Open Innovation Project. By enabling quantitative simulation of biological responses and prediction of drug mechanisms, we are helping to shape a next-generation bioevaluation platform in the era of AI transformation.
NetTargets has been selected as one of the top 10 semifinalists among hundreds of drug discovery startups worldwide. The AI Discovery Award is an annual recognition by Nebius AI, a European AI-centric public cloud provider with global reach.
